



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 37/02* (2006.01)
A61P 27/02 (2006.01)
- (21) **International Application Number:**
PCT/US2024/060579
- (22) **International Filing Date:**
17 December 2024 (17.12.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/611,151 17 December 2023 (17.12.2023) US
63/656,371 05 June 2024 (05.06.2024) US
63/696,278 18 September 2024 (18.09.2024) US
- (71) **Applicant: VIRIDIAN THERAPEUTICS, INC.**
[US/US]; 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US).
- (72) **Inventors: BEDIAN, Vahe;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US). **DICKINSON, Brent;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US). **FOSTER, Kelly;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US).

- (74) **Agent: KIM, Sang-A** et al.; Proskauer Rose LLP, One International Place, Boston, Massachusetts 02110 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- (54) **Title:** COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE




FIG. 1

- (57) **Abstract:** Methods of treating patients with thyroid eye disease are provided for herein, such as by administering subcutaneously antibodies and compositions that bind to and/or antagonize IGF-1R.

Published:

— with international search report (Art. 21(3))